Vir Biotechnology (VIR) Total Current Liabilities (2018 - 2026)

Vir Biotechnology has disclosed Total Current Liabilities across 9 years of filings, most recently posting $73.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $73.6 million, down 46.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.6 million (down 46.42% YoY), and the FY2025 annual result was $92.8 million, down 22.44% from the prior year.
• Total Current Liabilities came in at $73.6 million for Q1 2026 at Vir Biotechnology, down from $92.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $702.4 million in Q1 2022 to a low of $73.6 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $137.3 million (2025), against an average of $233.1 million.
• Across the five-year window, Total Current Liabilities soared 227.25% in 2022 and slumped 80.62% in 2024, its largest moves.
• Vir Biotechnology's Total Current Liabilities stood at $511.0 million in 2022, then plunged by 65.68% to $175.4 million in 2023, then tumbled by 31.78% to $119.7 million in 2024, then declined by 22.44% to $92.8 million in 2025, then fell by 20.75% to $73.6 million in 2026.
• The last three Total Current Liabilities figures came in at $73.6 million (Q1 2026), $92.8 million (Q4 2025), and $75.2 million (Q3 2025), per Business Quant data.